Call Us @ 0172 - 4680800 | info@indswift.com | NETWORKS | NSE - BSE

Investors

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 30TH JUNE, 2003
(RS. IN LACS)
PARTICULARS
3 Months 30.06.2003 (UNAUDITED)
3 Months 30.06.2002 (UNAUDITED)
12 Months 31.03.2003 (UNAUDITED)
INCOME FROM OPERATIONS
4904.08
4464.51
17828.63
OTHER INCOME
8.51
15.75
168.18
TOTAL INCOME
4912.59
4480.26
17996.81
TOTAL EXPENDITURE
4381.97
4062.00
16128.02
DECREASE IN STOCK IN TRADE
25.46
84.96
-665.06
CONSUMPTION OF RAW MATERIAL
3681.07
3283.95
14275.96
STAFF COST
150.62
126.69
596.86
OTHER EXPENSES
524.82
566.40
1920.26
INTEREST
164.24
83.65
574.92
DEPRECIATION
22.47
18.56
78.07
PROFIT BEFORE TAX
343.91
316.05
1215.80
PROVISION FOR TAX
25.79
23.70
91.19
PROVISION FOR DEFERRED TAX
13.36
21.75
59.37
EXCESS PROVISION WRITTEN BACK INCOME TAX FOR THE PREV.YEAR
-
-
-2.60
NET PROFIT
304.76
270.60
1067.85
PAID UP EQUITY CAPITAL
439.50
439.50
439.50
RESERVES EXCLUDING REVALUATION RESERVES
-
-
-
EPS
6.93
6.16
24.30
NOTES:
1. During the quarter under review, the turnover and the net profit of the company has increased by 58.53% & 55.16% respectively as compared to the corresponding quarter of the previous year.

2. As per IMS April 2002 Report the Company is growing at a compounded annual growth rate of over 89%and is ranked among the top fastest growing companies of India.

3. During the Quarter Company received the DCGI approval for the marketing of the fastest growing Anti-Depressant Drug “Citalopram” in India.

4. The Company is exclusively in the Pharmaceutical business segment.

5. The above financial results were taken on record by the Board at its meeting held on 27th July, 2002.
 
By Order of the Board
For Ind-Swift Limited
 
Dated: 31.07.2003
 
(Sanjeev Rai Mehta)
Place: Chandigarh
 
Managing Director